Why the study?
Does early initiation of PCSK9i improve LDL-C reduction and reduce early hospital readmissions in patients with acute coronary syndrome?
Does early initiation of PCSK9i improve LDL-C reduction and reduce early hospital readmissions in patients with acute coronary syndrome?
Early initiation of PCSK9i in ACS patients effectively reduces LDL-C and early hospital readmissions.
Answers are grounded in this paper and cite their sources.
Supports early PCSK9i initiation post-ACS; extends limited evidence on LDL-C lowering and readmission reduction.
PCSK9i are highly effective in early reduction of LDL-C along with reduction of early hospital readmissions post-ACS.
No takes yet. Share an insight, caveat, or question.
Nagendra et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: